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Abstract
Background: Retinoid Receptors are involved in development and cell homeostasis. Alterations
of their expressions have been observed in lung cancer. However, retinoid chemoprevention trials
in populations at risk to develop such tumors have failed. Therefore, the pertinence of new clinical
trials using second generation retinoid requires prior better understanding of retinoid signalling.
This is our aim when validating extensively research tools, focused on Retinoic Acid Receptor beta,
whose major role in lung cancer is documented.
Methods: Biocomputing was used to assess the genomic organization of RAR beta. Its putative
RAR-beta1' promoter features were investigated experimentally. Specific measures realized, with
qRT-PCR Syber Green assays and a triplex of Taqman probes, were extensively validated to
establish Retinoid Receptors mRNAs reference values for in vivo normal human bronchial cells, lung
tumors and cell lines. Finally, a pan-RAR-beta antibody was generated and extensively validated by
western-blot and immunoprecipitation.
Results: No promoter-like activity was found for RAR-beta1'. RAR-beta2 mRNAs increase signs
the normal differentiation of the human bronchial epithelium while a decrease is observed in most
lung cancer cell lines. Accordingly, it is also, along with RXR beta, down-regulated in lung tumors.
When using nuclear extracts of BEAS-2B and normal lung cells, only the RAR-beta2 long protein
isoform was recognized by our antibody.
Conclusion: Rigorous samples processing and extensive biocomputing, were the key factors for
this study. mRNA reference values and validated tools can now be used to advance researches on
retinoid signalling in the lung.
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Background
Vitamin A and its active derivatives referred to as retinoids
are non-steroid hormones which play a critical role in the
development and homeostasis of vertebrate tissues [1-3].
They exert their actions by regulating the expression of tar-
get genes, influencing likewise: cell proliferation, differen-
tiation and apoptosis through nuclear Retinoid Receptors
(RRs) binding [4]. Six different RRs are encoded by sepa-
rate genes (Retinoic Acid Receptors (RAR) α, β, γ and Retin-
oid X Receptors (RXR) α, β, γ) with at least two isoforms for
each, depending upon promoter usage and alternative
splicing [5]. RAR/RXR heterodimers are the functional
units transducing the retinoid signal when binding Retin-
oic Acid (RA), co-activators and DNA response elements
(RAREs) of target genes [6,7]. RXRs form homodimers
and/or heterodimers with RARs and most other nuclear
receptors for extended effects [8,9].
Alterations in RRs expressions are observed in several can-
cers. The RARα gene is involved in acute promyelocytic
leukemia [10] and is also silenced through promoter
hypermethylation in human breast carcinoma cell lines
[11]. In lung, breast and prostate tumors, the expression
of RARβ is found lost or down-regulated through uncon-
stant promoter hypermethylation, but without any dele-
tion or mutation of this gene [12-15]. The involvement of
RARγ in cancer is less known [16]. Down-expressions of
RXRs have been reported in prostate and thyroid carci-
noma [17,18]. RARβ has been mostly studied in lung can-
cer [19-21]. For this serious disease, primary prevention,
that is tobacco eviction, remains the best goal. However,
considering the overall poor results obtained by the cur-
rent treatments, it seems important to offer to "at risk"
subjects a secondary chemoprevention. Retinoids have
been used with such a goal but have given deceiving
results for still unexplained reasons [22,23]. This under-
lines the need for more knowledge about retinoid signal-
ling in the normal human lung.
In this context, we recapitulated the informations availa-
ble in silico for the human RARβ in order to update its
genomic organization. The activity of a putative promoter
RAR-beta1' was assessed experimentally. Reference values
for RRs mRNAs were measured in Normal Human Bron-
chial Epithelial cells (NHBE) with qRT-PCR Syber Green
assays and a triplex of Taqman probes. Conceived to save
invaluable bronchial mucosa samples, the reliability of
this last qRT-PCR tool was extensively validated. Hence, it
was used to measure the relative RRs mRNAs levels in lung
tumors and cell lines. Finally, contrary to commercial
antibodies, our pan-RARβ antibody immunoprecipitated
a single band of protein in nuclear extracts of BEAS-2B
and NHBE cells. Its molecular weight and further amino
acid sequencing demonstrated that it corresponds to the
RARβ2 protein isoform. Rigorous samples processing, like
extensive biocomputing analysis were the key factors for
the realization of this study. Validated tools are now avail-
able for future investigations on Vitamin A/retinoid sig-
nalling in the lung.
Methods
Samples
This study was approved by the French Medical Ethical
Committee for Bioresearch of Lorraine. All the samples
were provided by the "Centre de Ressources Biologiques
du Centre Hospitalier Universitaire de Nancy", an ISO
9001-2000 certified biobank. Informed consents were
obtained from patients operated upon for lung cancer
who donated their samples to the biobank. Samples col-
lections have been extensively described in [24]. All the
reagents were purchased from Sigma-Aldrich (L'Isle
d'Abeau Chesnes, Saint-Quentin Fallavier, France), unless
mentioned. Twelve Squamous Cell epidermoid Lung
Cancer (SqCLC) samples were obtained from different
patients. Fourty μm frozen sections were cut and further
dissected by JMV, our pathologist, after quick staining
with RNAse-free azur blue solution. Contaminating nor-
mal tissues were removed and RNA was further prepared
to give 90% tumoral mRNA [24].
Trachea and the beginning of the two main bronchi were
obtained from ten donors. All subjects were kept under
artificial respiration until the specimens were collected.
Then, samples were bathed in cold RPMI-1640 complete
medium supplemented with 10% Foetal Calf Serum, 50
units/mL penicillin, 50 μg/mL streptomycin and 5 μg/mL
fungizone for express transport to the laboratory. There,
they were cut open and the mucosa was washed with
RPMI complete medium before being scratched with the
back of a scalpel blade to give "Normal differentiated
Human Bronchial Epithelial cells" or NHBE: our reference
tissue sample. Pooled NHBE were kept frozen at -20°C
until further processing. Histological examination dem-
onstrated that such samples contained mainly differenti-
ated bronchial cells. The remaining scratched mucosa was
dissected out from the bronchi and cut into small explants
to give rise to "Cultured undifferentiated Human Bron-
chial Epithelial cells" (CHBE) in LH9 medium (Cambrex
Bio Sciences, Emerainville, France). Cells were grown for
two weeks with regular medium change as in [25]. A week
later, explants were detached from dishes and cultured
again twice. At confluence, CHBE were scrapped and proc-
essed like NHBE for RNA purification. Histological exam-
ination revealed mostly undifferentiated basal bronchial
cells. The smooth muscle sheaths from the back of the tra-
chea were obtained by dissection and were cut frozen as
20 μm sections. Skin samples were collected from three
different female patients undergoing fat reduction and
were cut also as 20 μm frozen sections parallel to the basal
membrane. Quick histological examination of every thirdBMC Cancer 2009, 9:423 http://www.biomedcentral.com/1471-2407/9/423
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section verified that collection was restricted to epidermis.
All specimens were processed as NHBE to prepare RNA.
The BEAS-2B [CRL-9609] transformed human bronchial
cell line, the pleural mesothelioma NCI-H513, the Small
Cell Lung Cancer NCI-H69 [HTB-119], the Non-Small
Cell Lung Cancers (NSCLC) NCI-H1648 [CRL-5882],
NCI-H2087 [CRL-5922] and NCI-H2342 [CRL-5941], the
lung A549 [CCL-185] and the breast MDA-MB-231 [HTB-
26] adenocarcinoma were purchased from the American
Type Culture Collection (Rockville, MD, USA). All were
propagated at 37°C in a 96% humid atmosphere with 4%
CO2 in RPMI-1640 complete medium to confluence to
prepare RNA as for CHBE.
RNA preparation
In order to facilitate RNA solubilization, all frozen cut
samples were first passed through a 23-Gauge needle.
Total RNA was purified using the RNeasy Mini Kit (Qia-
gen, Courtaboeuf, France) with DNA digestion and integ-
rity verification steps according to the manufacturer's
instructions and our internal quality controls. Then, RNAs
were diluted to a final concentration of 125 ng/μL and
kept frozen at -20°C.
cDNA synthesis
For each sample, 3 aliquots of 1 μg total RNA were reverse
transcribed using the First-Strand cDNA Synthesis Kit (GE
Healthcare Life Sciences, Orsay, France) according to the
manufacturer's instructions. Serial dilutions of each cDNA
at 1/5, 1/10, 1/50, 1/100 and 1/500 were performed.
Drawing the human RARβ genomic region
Genome databanks were mined to construct an extended
RARβ  genomic organization (Figure 1). Relevant PCR
primers were designed to evince the presence of non vali-
dated mRNA transcripts: [GenBank:DA240288], [Gen-
Bank:U52076], [GenBank:DC376623] and
[GenBank:DQ083391] (Additional File 1). The PCR pro-
gram was: 94°C for 2 min, followed by 30 cycles: 94°C for
20 s, 60-64°C for 20 s, 72°C for 45 s and then 10 min at
72°C. Amplicons were analyzed by agarose gel (2%) elec-
trophoresis. The sequences of the 5' flanking regions (-
1500/-50) of each upstream transcript were further
screened for promoter features with: Proscan version 1.7
[26], Promoter 2.0 [27], and Promoter Inspector [28].
Additional analysis with MatInspector [28] and
TFSEARCH [29] identified transcription factors DNA
binding sites. In order to evince any RARE, these
sequences were also analyzed by ModelInspector [28]
using a RARE DR5 weight matrix generated from the fol-
lowing RARE DR5 model sequence: [pu]g [g/t]tca = [ag]g
[gt]tca/tga [ac]c [ct]. Finally, the orthologous conservation
of the mouse RAR-beta1 and the human RAR-beta1' pro-
moters were investigated using the Eldorado comparative
genomics module [28].
RAR-beta1' promoter analysis
Using NHBE DNA, this 1434 bp RARE containing
sequence [chr3:25,355,884-25,357,317] was amplified by
PCR in both forward and reverse orientations. Amplicons
were sequenced for verification and then cloned into
pGL3 Basic Luciferase Reporter Vectors (Promega, Char-
bonnières-les-Bains, France), using MluI and XhoI restric-
tion sites. The forward PCR primers were: (F)5'-
aatgcacgcgtccaattcaacgctttctgtacc-3' (R)5'-aacggctcgag-
gctctgtcaatggcttctcc-3', and the reverse primers were: (F)5'-
aacggctcgagccaattcaacgctttctgtacc-3' (R)5'-aatgcacgcgt-
gctctgtcaatggcttctcc-3'. BEAS-2B and MDA-MB-231 cell
lines were co-transfected in triplicate wells for 24 h and 48
h with the pGL3+RAR-beta1' plasmid constructs (firefly
Luciferase) and the pRL-TK internal control reporter vec-
tor (Renilla Luciferase). Transfections were performed in
6-well plates using the jetPEI™ transfection reagent (Poly-
plus Transfection, Strasbourg, France) according to the
manufacturer's instructions. The activity of the RAR-beta1'
promoter was assessed by Luciferase reporter assays and
carried out with the Dual-Glo™ Luciferase Assay reagent
(Promega, Charbonnières-les-Bains, France) following
the manufacturer's instructions. Resulting fluorescence
was measured using a Victor3 ™ plate reader (PerkinElmer,
Courtaboeuf, France) with fluorescence readings for fire-
fly Luciferase (pGL3+P1'-RARβ) normalized to Renilla
Luciferase (pRL-TK).
Quantitative Real-Time PCR
The qRT-PCR primers and Taqman probes used in this
study are presented in the Additional File 1. Primers for β-
Actin were chosen in the gene 3' untranslated region as a
RNA integrity control. The "RARβ" primers (exon 8) target
all the RARβ  transcripts generated from the RAR-beta2
promoter, while the "RARβ2" primers (exon 1) are spe-
cific to the RARβ2  transcript isoform. Primers used in
Syber Green or in Taqman assays are identical for RARα
and RXRβ, while they were made in different parts of the
5' end of the RARβ transcripts in order to cross confirm the
results obtained with either the Taqman assays (primers
located in the exons 6/7 junction) or with the Syber Green
assays (primers located in the exon 8). No reliable primers
were found for RXRγ  (multiple single nucleotide poly-
morphisms). All primers, 5' FAM-RARβ-3' TAMRA and 5'
Texas Red-RXRβ-3' Deep Dark Quencher-2 Taqman
probes, were purchased from Eurogentec (Angers,
France). The 5' VIC-RARα-3' TAMRA probe was synthe-
sised by Applied Biosystems (Courtaboeuf, France).
For Syber Green assays, a β-Actin standard curve was first
performed using the full cDNA cascade dilutions of each
cDNA sample in triplicate and a RotorGene 6000 (Corbett
Research, Labgene, Archamps, France). RRs were meas-
ured for the sole dilutions: 1/10, 1/50 and 1/100, in trip-
licates. Ten μL final volume contained: 4 μL of cDNA, 0.14
μL of 10 μM primers (140 nM each), 5 μL of AbsoluteBMC Cancer 2009, 9:423 http://www.biomedcentral.com/1471-2407/9/423
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QPCR SYBR Green Mix (Thermo Fisher Scientific, Court-
aboeuf, France) and 0.72 μL of water. The PCR program
was: 95°C for 15 min, followed by 50 cycles of 95°C: 10
s, 60°C: 20 s and 72°C: 20 s. Further melt curve analysis
was conducted from 70°C to 95°C (0.5°C every 15 s). All
amplicons were sequenced for confirmation. Taqman
assays were performed for the same cDNA dilutions as
above in duplicates. Twenty five μL final volume assays
contained: 5 μL of cDNA, 0.5 μL of primers (200 nM
each), 0.25 μL of probes (200 nM each), 12.5 μL of
QuantiTect Multiplex PCR Mastermix (Qiagen, Court-
aboeuf, France) and 3.75 μL of water. The PCR program
began with a Taq Polymerase activation step at 95°C for
15 min, followed by 50 cycles of 94°C: 60 s and 60°C: 90
s. Assays with one probe at a time vs the triplex of probes
were first compared in order to optimize equal final qPCR
efficiencies.
Raw qRT-PCR data were collected with the RotorGene
6000 Series Software version 1.7.87. The comparative
quantification approach [30] implemented within the
built-in software was used to compute the second deriva-
tive of each amplification curve whose peak corresponds
to the point at which the most efficient amplicon synthe-
sis occurs. For each measure, the software determines a
"Take-Off Point (TOP)" value, 80% before the peak and
an "Amplification Efficiency (AE)" from the slope of the
section of the curve between the TOP and the peak. For
each gene and sample analyzed, all the TOP and AE values
from the replicates were averaged to calculate the mean
Take-Off Point (mTOP) and the mean Amplification Effi-
ciency (mAE) values with their Standard Deviations (SD)
(Additional File 2). The quality of each standard curve was
assessed by its associated R2 value, computed with auto-
matic fluorescence threshold settings by the RotorGene
software.
For statistical analysis, the qPCR data were first exported
into the Bestkeeper© version 1 software [31] to determine
the most stable and common reference genes across all the
samples. Validated reference genes were then combined
into a Bestkeeper© index for the normalization of RRs
expression data. Then, the Rest-RG© software [32] was
used to transform the raw qPCR data into normalized RR
x-fold expression ratios (R). It uses the mathematical
model described by Pfaffl et al. [33], that combines gene
Schematic representation of the RARβ genomic context Figure 1
Schematic representation of the RARβ genomic context. Black arrows represent introns and black blocks are tran-
scribed RARβ exons while grey blocks and arrows represent untranscribed spliced regions. All the promoters regions are grey 
circled while grey compact blocks indicate DR5 RAREs and grey rounds indicate CpG islands. P1, P1', P1", P2 and P3 indicate 
corresponding RAR-beta promoter regions. [GenBank:NM_000965] and [GenBank:NM_016152] are the Refseq IDs corre-
sponding to the RARβ transcript isoforms 1 and 2 respectively. [GenBank:NM_000965] encodes the RARβ2 protein [Swiss-
Prot:P10826-2] while [GenBank:NM_016152], resulting from the alternate splicing of [GenBank:NM_000965] at exon 3, 
encodes the RARβ4 protein [Swiss-Prot:P10826-3]. [GenBank:DA240288] and [GenBank:DC376623] are Expressed Sequence 
Tags. [GenBank:U52076] and [GenBank:DQ083391] are GenBank mRNAs. [GenBank:DC376623] and [GenBank:DQ083391] 
have specific first exons and share their other exons with [GenBank:NM_000965].BMC Cancer 2009, 9:423 http://www.biomedcentral.com/1471-2407/9/423
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quantification and normalization, according to the fol-
lowing equation: Ratio (R) = (Etarget)ΔC
target
(control-sample)/
(Eref)ΔCt
ref
(control-sample).
Ratios were computed using a Pair Wise Fixed Realloca-
tion Randomisation Test© and plotted with Standard Error
(SE) estimation via a Taylor algorithm. Computations
were based upon the sample-specific mAE (mAE×E) and
the corresponding mTOP deviations (ΔmTOP×ΔCt) for
each sample tested vs the control sample: NHBE. In each
sample tested, RRs genes expressions were also normal-
ized by the optimal combination of reference genes previ-
ously defined by Bestkeeper©.
Western-Blot and Immunoprecipitation
To produce our pan-RARβ antibody, the following syn-
thetic peptide: GHEPLTPSSSGNTAEHSPSI, correspond-
ing to the F2 region, common to all the human RARβ
proteins, was chosen to immunise rabbits and was puri-
fied by affinity chromatography (Proteogenix, Strasbourg,
France). For western-blot analysis, nuclear extracts were
prepared from BEAS-2B and NHBE cells as described in
[34]. They were fractionated by SDS (1%) poly-acryla-
mide gel electrophoresis (12%) and electrotransferred
onto nitrocellulose filters. After blocking with PBS con-
taining 3% non-fat powdered milk, the filters were immu-
noprobed with our polyclonal RARβ antibody (dilution
1:500) for 2 h, extensively washed in PBS containing
0.05% Tween 20, and then incubated for 1 h at room tem-
perature with an anti-rabbit peroxidase-conjugated anti-
body (dilution 1:40,000) (Jackson ImmunoResearch,
West Grove, PE, USA). Specific complexes were revealed
by chemiluminescence detection (Super Signal West
Dura, Pierce Biotechnology, Rockford, IL, USA) according
to the manufacturer's protocol. For immunoprecipitation
analysis, NHBE nuclear extracts (1 mg) were incubated
with immobilized Protein A cross-linked to the antibody,
using the Seize X Protein A Immunoprecipitation Kit
(Pierce Biotechnology, Rockford, IL, USA) according to
the manufacturer's protocol. The immunoprecipitated
proteins were detected as above by immunoblotting and
chemiluminescence. Further sequencing of the immuno-
precipitates were realized by the "core protein platform"
of the University of Nancy.
Results and Discussion
Investigation of the human RARβ genomic region (Figure 1)
The different isoforms encoded by RARβ  were first
described in mice. Two murine promoters have been char-
acterized: RAR-beta1, encoding the RARβ1 and RARβ3
proteins, and RAR-beta2, encoding RARβ2 and RARβ4
[35,36]. Then in humans, the RARβ2 protein [Swiss-
Prot:P10826-2], encoded by a CpG island and RARE con-
taining RAR-beta2 promoter region, was reported [37].
The RARβ4 protein isoform [Swiss-Prot:P10826-3], gener-
ated from the alternate splicing of the RARβ2 mRNA at the
exon 3, was further described [5]. A human foetal protein
isoform, RARβ1 [Swiss-Prot:P10826-1], also expressed in
small cell lung cancers has been identified [38]. However,
neither the corresponding mouse RAR-beta1-like pro-
moter nor the RARβ1 and RARβ3 transcripts have been
fully characterized in human cells. Another protein iso-
form, RARβ5, has been characterized in both normal and
malignant human breast cells [39]. It is supposed to con-
tribute to the resistance of the cancerous cells to retinoids.
This isoform is encoded by a cryptic distinct RAR-beta3
promoter, located in the first intron of the RARβ2 tran-
script [39]. Finally, a RARβ1' transcript isoform, with a
specific first exon, has been reported [40]. However, the
corresponding protein sequence is not described. This
transcript is encoded by a distinct promoter RAR-beta1"
and is expressed in normal human lung and normal RA-
sensitive BEAS-2B cells but it is suppressed in RA-resistant
BEAS-2B, in some lung cancer cell lines and lung tumors
[40].
Based upon these reports, we mined databanks to draw in
silico the human RARβ genomic region (Figure 1). Two
RARβ  Refseq transcripts, [GenBank:NM_000965] and
[GenBank:NM_016152], are reported on chromosome 3,
strand +. They are respectively associated to the RARβ2
(long) and the RARβ4 (short) isoforms, which are tran-
scribed from the well-characterized RAR-beta2 promoter
(represented as P2 on Figure 1). These two transcripts
were detected in all the samples tested when using our
"RARβ" and "RARβ2" qRT-PCR primers (Additional File
1, Figure 2). No Refseq IDs were found for the RARβ1,
RARβ1' and RARβ5 isoforms in the databanks. However,
four unvalidated transcripts are reported in the region
upstream of RAR-beta2: [GenBank:DQ083391], [Gen-
Bank:DC376623], [GenBank:U52076] and [Gen-
Bank:DA240288] (Figure 1). Two of these transcripts have
a specific first exon in their respective sequences and share
their other exons with RARβ2  (Figure 1). [Gen-
Bank:DC376623] is an Expressed Sequence Tag and [Gen-
Bank:DQ083391] is described as a mRNA entry that
contains the partial coding sequence of RARβ1'. Interest-
ingly, we found that the qRT-PCR primers used in [40] to
amplify the RARβ1' isoform are located in the exons 1 and
2 of this unvalidated trancript. We designed specific PCR
primers (Additional File 1, Figure 1) in order to establish
the existence of these four upstream transcripts. However,
none corresponding amplicons were found in the selected
cells: NHBE, CHBE, SMC, A549, H2087, H2342 and
BEAS-2B. These results were especially surprising for
[GenBank:DQ083391], as the primers we designed are
located in the exons 1/2 junction of the transcript and
overlap with those previously used in [40] to amplify
RARβ1'.
The upstream sequence of each unvalidated transcript (-
1500/-50) was further screened using online tools toBMC Cancer 2009, 9:423 http://www.biomedcentral.com/1471-2407/9/423
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detect the features of a putative additional RAR-beta pro-
moter region. No canonical promoter features (TATA box,
...) were found, but two degenerate DR5 RARE motifs were
identified within the upstream sequences of [Gen-
Bank:U52076] and [GenBank:DQ083391], near their
respective specific first exons (Figure 1). Additionally, a
CpG island was found in the upstream sequence of [Gen-
Bank:U52076]. This last region (indicated as P1" on Fig-
ure 1) was previously explored by Petty et al. [40] and it
was therefore not reinvestigated experimentally in this
study. However, we searched for other possible alternate
RAR-beta promoters. In silico comparative genomics indi-
cated an orthologous conservation between the mouse
RAR-beta1 promoter region and the upstream sequence of
[GenBank:DC376623]. This region (indicated as P1 on
Figure 1) corresponds to the region amplified by Houle et
al. when cloning the 5' end of the RARβ1 cDNA [38].
Another interesting orthologous promoter conservation
was found within the upstream sequence of [Gen-
Bank:DQ083391] for chimp RARβ  (99%) [Genom-
atix:GXP_1213141] and rhesus monkey RARβ  (95%)
[Genomatix CompGen promoter]. This conserved region
(indicated as P1' on Figure 1) was further investigated
experimentally but no promoter-like activity was demon-
strated in reporter assays. This might be a feature of weak
nuclear receptors.
Relative expressions of RRs mRNAs
Reference values for RRs mRNAs expressions were first
determined in normal lung tissues (NHBE), then the rela-
tive levels of RRs mRNAs were measured in several cell
lines, comparing the results obtained with the two qRT-
PCR methodologies: Syber Green and a triplex of Taqman
probes. The primers and probes used in this study are
listed in Additional File 1. The raw qRT-PCR data are reca-
pitulated in Additional File 2. R2 values ranging from
0.965 to 1, mTOP SD<15% and mAE SD<10% demon-
strates the reproducibility of each assay.
Additional File 3 shows the results obtained from the
Bestkeeper© analysis to select the best combination of ref-
erence genes used for the normalization of the qRT-PCR
data. In addition, when demonstrating the stability of the
selected genes, the quality of each sample was also system-
atically assessed by Bestkeeper© as described in [31]. SD
values < 1 demonstrates the overall inter-sample expres-
sion stability for β-Actin (0.56), RARα (0.60 with Sybr
Green and 0.67 with the Taqman probe) and RXRβ (0.75
with Sybr Green and 0.60 with the Taqman probe). SD
value > 1 sustained gene expression variability across sam-
ples and therefore exclusion from the computation of the
Bestkeeper© index. Using only the three stable genes, their
combinations were tested to obtain the most reliable Best-
keeper© index parameters. Although RARα correlated well
RARβ and RARβ2 relative expression ratios Figure 2
RARβ and RARβ2 relative expression ratios. RARβ x-fold ratios (R) were computed by Rest-RG®, based on 2-log of 
absolute gene regulation, with their associated standard errors. In the different samples RARβ expressions are normalized to 
reference genes and NHBE expressions. The ratios significatively different from NHBE (p-values < 0.05) are indicated with 
asterisks.BMC Cancer 2009, 9:423 http://www.biomedcentral.com/1471-2407/9/423
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with the Bestkeeper© index, its inter-sample wide variation
did not match with those of β-Actin and RXRβ (r < 0.5, p
> 0.05). RARα was therefore not considered as a relevant
reference gene in this case. In Syber Green assays, the opti-
mal Bestkeeper© index parameters were found for the com-
bination of β-Actin and RXRβ as reference genes. Indeed,
their expressions correlated well together (r = 0.76, p =
0.006) and a good correlation for each β-Actin (r = 0.96, p
= 0.001) and RXRβ (r = 0.92, p = 0.001) was observed
with the computed BestKeeper© index, which exhibited a
moderate SD variation of 0.64. This combination of refer-
ence genes was thus further used in each sample for the
normalization of RRs expression data obtained from the
Syber Green assays.
As a matter of fact, it is not possible to design a multiplex
of Taqman including the housekeeping gene, β-Actin, and
the RRs genes together because the gap of expression
between them is so wide that the amplification of β-Actin
will be inhibited when RRs become detectable for the
same qPCR cDNA inputs. Since the SD values associated
to the RARα and RARβ Taqman probes were > 1 (Addi-
tional File 3), they could not be used for the normaliza-
tion of the data obtained with the triplex of probes.
Therefore, a combination of β-Actin (Syber Green external
reference gene) and RXRβ  (Taqman internal reference
gene) was tested. The related Bestkeeper© index showed a
SD variation of 0.59 (Additional File 3). The values of the
selected reference genes correlated well together (r = 0.61,
p = 0.046) and also with the corresponding Bestkeeper©
index (r = 0.94, p = 0.001 for β-Actin and r = 0.84, p =
0.001 for RXRβ). This combination of reference genes was
thus used in each sample for the normalization of the data
generated from Taqman assays. It also allowed to perform
an accurate comparison between the significant relative
expression ratios obtained with both qRT-PCR methodol-
ogies.
For each sample, the RRs mRNAs expression ratios relative
to NHBE were next computed by the Rest-RG© software,
with a simultaneous normalization of the data by both
reference genes: β-Actin and RXRβ (Additional File 4). The
sample-wide relative levels of "RARβ" and "RARβ2"
amplicons are represented on Figure 2. Statistical signifi-
cance was determined using a Pair Wise Fixed Realloca-
tion Randomisation Test© (p-value < 0.05). We chose the
method reported by Pfaffl et al. [33] to determine the rel-
ative expressions of RRs mRNAs because it allows a relia-
ble normalization of the raw qRT-PCR data with an index
of stable reference genes. In this method, the computation
of each expression ratio is based upon the crossing point
deviation (ΔCP or ΔmTOP) for each sample vs the control
sample (NHBE). Furthermore, corrections for exact qRT-
PCR efficiencies (E or mAE) are taken into account, which
is not the case when computing relative expressions using
the standard curve or the ΔΔCP methods [41-43]. Such
normalizations are indeed very important, especially
when the expressions of several genes have to be com-
pared across numerous samples.
In Syber Green assays, the levels of "RARβ" amplicons var-
ied as follows: H69(0.32) > A549(0.16) > skin*(-2.20) >
CHBE*(-2.27) > SMC*(-2.48) > H2087*(-3.63) >
H2342*(-4.06) > BEAS-2B*(-4.54) > H513*(-4.68) >
H1648*(-5.63), while the levels of "RARβ2" amplicons
were ranked as follows: A549(-0.24) > H69(-0.23) >
SMC*(-3.03) > skin*(-3.29) > CHBE*(-3.35) > BEAS-
2B*(-5.63) > H513*(-5.64) > H2342*(-6.57) > H1648*(-
8.33). In H2087, the level of "RARβ2" amplicons was so
weak that it was not detected. In all the samples, the rela-
tive amounts of "RARβ" amplicons were always higher
than those observed for "RARβ2" (Figure 2). This is con-
sistent with the fact that the "RARβ" primers target the
common part of all the RARβ transcripts generated from
RAR-beta2, whereas the "RARβ2" primers are specific for
the sole RARβ2 transcript isoform. When compared to "in
vivo" differentiated NHBE, the relative levels of both
"RARβ" and "RARβ2" amplicons were always found at
lower levels in the samples tested. This, especially for the
"in vitro" undifferentiated CHBE cells, indicating that
RARβ is indeed very important in lung cells and that an
increase in RARβ expression signs the normal differentia-
tion of the human bronchial epithelial tissue. In addition,
the levels of "RARβ" and "RARβ2" amplicons observed in
skin and SMC were very similar to CHBE and their respec-
tive amounts were also significantly lower than in NHBE.
Concomitant and significant low levels of "RARβ" and
"RARβ2" amplicons were observed in H1648, H2087, and
H2342 (Figure 2), confirming the importance of RARβ in
NSCLCs [21,34,44,45]. That was not the case in both H69
and A549 cell lines whose "RARβ" and "RARβ2" ampli-
cons levels corresponded to those observed in NHBE.
The results obtained with the RARβ Taqman probe varied
as follows: A549(0.24) > H69(-0.40) > SMC*(-2.06) >
skin*(-2.21) > CHBE*(-2.87) > BEAS-2B*(-3.8). In
H1648, H2087, H2342 and H513, RARβ  was found
highly down-expressed and still detected by the Syber
Green assays but not by the Taqman assays (Figure 2). In
order to compare the data obtained with the RARβ Taq-
man probe vs the corresponding Syber Green data, a tissue
specific variation rate (VR) was computed when RARβ
amplicons were detected in both kinds of qPCR assays
and when the computed expression ratios were both sig-
nificant. All the resulting VR values are < 25% (Additional
File 4). This confirmed that, when detected, the RARβ
expression ratios generated by the two qRT-PCR method-
ologies were consistent. The triple Taqman assay was ini-
tially developed to save rare and invaluable mRNA
samples by simultaneously performing the detection of
three RR genes. Since there is twice as much cDNA in
Syber Green assays for a single RR amplification as there isBMC Cancer 2009, 9:423 http://www.biomedcentral.com/1471-2407/9/423
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in the Taqman probes assays to amplify three RRs, the sen-
sitivity of the Taqman assay is therefore at least twice that
of the Syber Green assay.
As RARα, RARγ and RXRα gave results with high SE values
for all the samples (Additional File 4), their expressions
were not considered significantly different from those
found for NHBE. Nevertheless, in Syber Green assays,
RARα  levels are ranked as follows: skin(0.61) >
SMC(0.13) > H1648(-0.02) > BEAS-2B(-0.26) > A549(-
0.59) > H513(-0.64) > H2087(-0.83) > CHBE(-0.95) >
H2342(-1.19) > H69(-1.30), while with the Taqman
probe it is: H1648(0.10) > skin(-0.22) > SMC(-0.28) >
A549(-0.31) > H513(-0.55) > BEAS-2B(-0.72) > H2087(-
0.74) > CHBE(-1.35) > H2342(-1.80) > H69(-1.92). The
sample-wide expression variation for RARα was very low,
except in H69 and H2342; this confirmed the low SD val-
ues previously found for this gene when using Bestkeeper©
(Additional File 3). Furthermore, RARα expression ratios
computed for Syber Green and the triplex of Taqman were
consistent within each sample where RARα  is found
slightly down-expressed (H69, H2342, CHBE, H2087,
H513, A549 and BEAS-2B) (Additional File 4). In skin,
SMC and H1648, the RARα levels were similar to those
observed in NHBE but the computed expression ratios
varied between the qRT-PCR methodologies. The RARγ
mRNA levels varied as follows: H513(2.27) > CHBE(1.63)
> skin(1.29) > A549(0.74) > BEAS-2B(0.57) > SMC(0.53)
> H2342(0.20) > H2087(-0.01) > H69(-2.32). In H1648,
a very poor amplification signal was detected for RARγ.
RXRα  transcripts levels were ranked as follows:
H513(2.05) > skin(1.53) > A549(1.14) > H1648(1.05) >
CHBE(0.15) > H2342(-0.07) > SMC(-0.14) > H2087(-
0.71) > BEAS-2B(-0.96) > H69(-1.75). In Syber Green
assays,  RARα,  RARγ  and  RXRα  were all found over-
expressed in skin when compared to the other samples.
Corresponding RRs protein levels were also previously
reported as highly expressed in this tissue [46].
Significant down-expressions of RXRs mRNAs were previ-
ously reported in lung tumors by comparison to their
respective matching normal tissues [47] and RXRβ was
reported as a biomarker of aggressivity for NSCLCs [48].
Nevertheless, in all the lung cancer cell lines tested in this
study,  RXRα  and  RXRβ  were not found differentially
expressed from the control tissue NHBE. Furthermore,
RXRβ, was demonstrated as stably expressed across all the
samples, and with both qRT-PCR methodologies. In this
context, it was therefore considered as a relevant reference
gene.
12 dissected SqCLC tumor samples were also analyzed
using β-Actin in Syber Green and the triplex of Taqman
probes. The resulting raw qRT-PCR data are recapitulated
in Additional File 5. β-Actin amplicons were detected in all
the samples tested with Syber Green as well as RARα
amplicons with the triplex of Taqman probes. Corre-
sponding qRT-PCR data were analyzed with Bestkeeper©
to check the expression stability of the genes across sam-
ples. The results are indicated in Additional File 6. SD val-
ues < 1 demonstrated the overall expression stability for
both β-Actin (0.89) and RARα (0.86) across tumoral sam-
ples. The related Bestkeeper© index showed a SD variation
of 0.85. The values of the selected reference genes corre-
lated well together (r = 0.78, p = 0.003) and with the cor-
responding Bestkeeper© index (r = 0.96, p = 0.001 for β-
Actin and r = 0.92, p = 0.001 for RARα). As previously, the
quality of each tumor sample was also confirmed by the
software [31]. Interestingly, although RARα  amplicons
were detected for each tumor sample analyzed with the
triplex of Taqman probes, no amplicons could be detected
for both RARβ and RXRβ (Additional File 5). This suggests
the deep concomitant down-expressions of these two RRs
genes in epidermoid lung tumors.
Western-Blot and Immunoprecipitation of RARβ
Commercial antibodies against RARβ gave in our hands
conflicting results in western-blots, with several protein
bands that are either attributed to phosphorylation or
degradation. Therefore, we validated extensively a new
pan-RARβ antibody directed toward a specific peptidic
sequence common to all the RARβ protein isoforms
described (F2 region). Using nuclear extracts of BEAS-2B
and NHBE cells, the antibody recognized a single band of
about 52 kDa in both western-blot (Figure 3, panel A) and
immunoprecipitation (Figure 3, panel B) experiments.
The amino acid sequencing gave the following sequence:
SSADHRVRLDLG (exon 5 of [NM_000965]) also com-
mon to all the RARβ proteins described, attesting for the
specificity of the antibody. The results obtained corre-
spond to the molecular weight expected for the RARβ2
protein, which is reported as a nuclear isoform of RARβ in
databanks. The RARβ4 protein, whose molecular weight
was previously reported at about 37 kDa [5] is reported as
a cytoplasmic isoform of RARβ in normal cells [49] and it
was accordingly not detected by our antibody in BEAS-2B
and NHBE nuclear extracts. The RARβ1' protein isoform
was previously characterized using whole cell extracts of
BEAS-2B and it was reported with a molecular weight of
about 47 KDa [40]. This isoform was also not detected by
our antibody in the nuclear extracts analyzed. These
results suggest that, if it is actually expressed in BEAS-2B
and NHBE cells, the RARβ1' protein is another short cyto-
plasmic isoform of RARβ. That is particularly interesting
as truncated isoforms of RARβ with "tumorogenic activ-
ity" were previously reported over-expressed in malignant
cells [50]. Indeed, these truncated isoforms are thought to
compete with RARβ2 in the nuclei of cancer cells; inhibit-
ing its cellular functions, enhancing the proliferation
process and contributing to the resistance of the cells to
retinoids.BMC Cancer 2009, 9:423 http://www.biomedcentral.com/1471-2407/9/423
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Conclusion
In this study, we used qRT-PCR analysis to measure RRs
mRNAs expressions in several samples and compared the
results obtained in Syber Green assays to those given by a
triplex of Taqman probes that was conceived to save inval-
uable mRNA samples. RARβ was the only RR gene whose
mRNA levels were found significantly different when
compared to NHBE. In these differentiated lung cells, the
RARβ  transcripts were found at their highest levels of
expression, indicating that an increase in RARβ mRNAs
signs the normal differentiation of the human bronchial
epithelium. In all the samples analyzed, RARβ2 was the
major transcript isoform that was detected. In addition,
the levels of RARβ2 varied concomitantly with the whole
levels of RARβ  mRNAs measured in each sample. To
evince the existence of additional RARβ isoforms, we reca-
pitulated the informations available in silico for the
human RARβ. Then, we investigated for the presence of
unvalidated  RARβ  transcripts and for the activity of a
putative RAR-beta1' promoter region. However, such tran-
scripts were not detected in the samples tested and no
activity was found for RAR-beta1'. This allowed to demon-
strate that the whole level of RARβ mRNAs observed in
each sample is represented by the transcripts isoforms
generated from the RAR-beta2 promoter. RARβ transcripts
were found highly down-expressed in NSCLC cell lines
and SqCLC tumors, which is a reported event in the proc-
ess of lung carcinogenesis. β-Actin and RARα expressions
were found stable across samples. As for RXRβ, although
its expression was found stable in normal lung cells and
cancer lines, a concomitant down-regulation was
observed with RARβ in SqCLC samples. This suggests a
possible role for this RR as an heterodimerization partner
for RARβ in the bronchial mucosa. Finally, RARβ2 was the
only protein isoform detected by our pan-RARβ antibody
in NHBE and BEAS-2B nuclear extracts, indicating that
short protein isoforms of RARβ were not present within
the nuclei of these cells. In our view, the research for spe-
cific human micro-RNAs targeting each of the RRs, as well
as RNA interference experiments, and the over-expres-
sions of full or truncated versions of RRs, would be of
great interest in order to complete our understanding of
the molecular mechanisms involved in the process of lung
carcinogenesis.
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Pan-RARβ antibody validation Figure 3
Pan-RARβ antibody validation. MW: Molecular Weight. 
Panel A: Western-Blot of BEAS-2B and NHBE nuclear 
extracts. lane 1: BEAS-2B nuclear extracts. lane 2: NHBE 
nuclear extracts. Panel B: Immunoprecipitation of BEAS-2B 
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